2nd Quarter - Report

FRESENIUS KABI USA LLC for FRESENIUS KABI USA LLC

Firm
Client
Income
—
Expenses
$75,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

7 issue areas, each in the filer's own words, with who lobbied on it and where.

Pharmacy PHA

PBM reform, including spread pricing, AWP setting and/or dispense rate policy, ASP policy, any willing pharmacy laws in Medicare, third party essential medicine testing

LobbyistCovered position, as disclosed
SARAH CHRISTINE D'ORSIE Congressman Tom Davis
STEVEN CHASE WALKER New Congressman Jodey Arrington

Contacted: SENATE; Centers For Medicare and Medicaid Services (CMS); HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA)

Trade (domestic/foreign) TRD

Sec. 232 investigation on pharmaceutical sector, tariffs, Buy America policies, Most Favored Nations Executive Order, reciprocal tariffs, essential medicines drug shortages related to trade agreements.

LobbyistCovered position, as disclosed
SARAH CHRISTINE D'ORSIE Congressman Tom Davis
STEVEN CHASE WALKER New Congressman Jodey Arrington

Contacted: HOUSE OF REPRESENTATIVES; Patent & Trademark Office (PTO); White House Office; Centers For Medicare and Medicaid Services (CMS); Commerce, Dept of (DOC); Executive Office of the President (EOP); Health & Human Services, Dept of (HHS); SENATE; U.S. Trade Representative (USTR); Food & Drug Administration (FDA)

Medicare/Medicaid MMM

PBM reform, patent reform, ASP reform, international reference pricing, IRA Medicare negotiation, inflation penalty, most favored nations executive order, AWP reform, U.S. manufacturer preferencing, Medicare conditions of participation relating to resiliency standards linked to government reimbursement, 340b reform including PBM-owned 340b pharmacies, Medicare formulary policy and specialty tier reform, generics on generic tiers, Medicaid generics penalty, IRA inflationary penalty, manufacturer discount program

LobbyistCovered position, as disclosed
SARAH CHRISTINE D'ORSIE Congressman Tom Davis
STEVEN CHASE WALKER New Congressman Jodey Arrington

Contacted: HOUSE OF REPRESENTATIVES; SENATE; Food & Drug Administration (FDA); Centers For Medicare and Medicaid Services (CMS)

Taxation/Internal Revenue Code TAX

BEAT, AMT, U.S. manufacturing incentives

LobbyistCovered position, as disclosed
SARAH CHRISTINE D'ORSIE Congressman Tom Davis
STEVEN CHASE WALKER New Congressman Jodey Arrington

Contacted: HOUSE OF REPRESENTATIVES; White House Office; SENATE

Health Issues HCR

Drug pricing, PBM Reform, patent reform, biosimilars, generics, medical devices, FDA approvals, DEHP

LobbyistCovered position, as disclosed
SARAH CHRISTINE D'ORSIE —

Contacted: Patent & Trademark Office (PTO); SENATE; HOUSE OF REPRESENTATIVES

Manufacturing MAN

Buy America legislation, tariffs, tax incentives, regulatory barriers to generic and biosimilar launches, patent waivers

LobbyistCovered position, as disclosed
SARAH CHRISTINE D'ORSIE —
STEVEN CHASE WALKER —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Tariff (miscellaneous tariff bills) TAR

Section 232 investigation into pharmaceuticals and unfair trade practices

LobbyistCovered position, as disclosed
SARAH CHRISTINE D'ORSIE —
STEVEN CHASE WALKER —

Contacted: U.S. Trade Representative (USTR); Executive Office of the President (EOP); SENATE; HOUSE OF REPRESENTATIVES; Commerce, Dept of (DOC)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.